trimeprazine-tartrate and Sleep-Wake-Disorders

Infant sleep disturbance involving chronic night waking and resistance to settling to sleep or returning to sleep is a common problem for families with children 6-27 months old. Prescription and nonprescription sedatives are frequently administered without clear evidence that they are effective as either long-term or short-term palliatives. Trimeprazine tartrate, administered either 15 mg/5 mL or 30 mg/5 mL, was compared with both baseline and placebo in a multiple-baseline-across participants, double-blind study. No clinically significant effects of the low dose were detected, whereas the effects of the high dose were not consistently replicated across nor within participants. During active drug treatment, only 2 of 12 children achieved Sleep Behaviour Scale scores indicative of nonproblem sleep. Trimeprazine tartrate is not recommended as a pharmacological treatment for infant sleep disturbance unless as an adjunct to a behavioral therapy program.

Topics: Child, Preschool; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Individuality; Infant; Male; Sleep; Sleep Wake Disorders; Trimeprazine

A double-blind trial using trimeprazine tartrate was carried out in 22 children with severe waking problems. On parental verbal reports sleep was significantly improved on the drug compared with the original baseline and the placebo, but diaries kept by the parents showed that this improvement was clinically only moderate, with many wakeful nights still occurring. Taking the drug produced no permanent effect on sleep patterns and a follow-up of 14 children 6 months later showed persisting sleep problems in the majority.

Topics: Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; Infant; Male; Sleep Wake Disorders; Trimeprazine

Topics: Child, Preschool; Conditioning, Psychological; Humans; Infant; Sleep Wake Disorders; Trimeprazine